semaglutide approval mash CDSCO Clears Wegovy for — India's First GLP-1 for Liver Disease, India's drug regulator CDSCO approved Novo Nordisk's Wegovy (semaglutide 2.4mg) on 17 July 2026 for MASH, based on Semaglutide, a GLP-1R agonist, is

Developed by leading scientists, we designed a new molecule and combined this with our proprietary formulation into a daily tablet that supports appetite regulation, metabolism, and longevity.* Evolv GLP-1 uses our own proprietary, science-backed ingredient designed to naturally activate GLP-1, a hormone in the body, for extended periods

When L-carnitine-L-tartrate or L-carnitine-fumarate is present, the weight ratio in the formulation of AD:L-carnitine-L-tartrate or AD:L-carnitine-fumarate is about 1:4 to about 1:12 and typically the ratio is about 1:6

Dizziness is classified as an uncommon side effect of GLP-1 receptor agonists such as Wegovy and Saxenda, affecting up to 1 in 100 people according to MHRA-approved product information

And the original contributions presented in the study are included in the articles and supplementary material

They produce no visual signal, no odor, no change in solution clarity

"New agreements to secure additional vaccine candidates for COVID-19"